Published in Blood Weekly, September 9th, 2004
"To assess the clinical, immunological and virological evolution in HIV-1 infected patients with CD4 T-cell count above 500/mm3, a historical cohort of 202 untreated and 96 patients treated with HAART was longitudinally studied (median follow up 36 months)," wrote investigators in France.
"Fourteen untreated and 2 treated patients experienced clinical progression (p=.09). The difference between baseline CD4 T-cell count and after 3 years was -240/mm3 in the untreated group vs. +19/mm3 in the HAART...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.